Prothena (PRTA) to Release Quarterly Earnings on Thursday

Key Points

• Prothena will report Q1 2026 results on May 7 after the market close (conference call 4:00 PM ET); analysts expect EPS of ($0.31) and revenue of $0.809 million.
• In the last quarter Prothena posted EPS of ($0.44) (slightly beating estimates) but minimal revenue ($0.02M); the stock opened at $10.64, was down 3.8%, and has a market cap of about $572.8M with a 52‑week range of $4.32–$11.69.
• Analyst coverage is mixed with an average rating of "Hold" and a consensus target of $21.67 (ratings include 1 Strong Buy, 4 Buy, 4 Hold, 2 Sell), while institutional investors own roughly 97.08% of the shares.

Prothena (NASDAQ:PRTA - Get Free Report) is projected to issue its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $0.8090 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.01. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.67 million. Prothena had a negative return on equity of 65.89% and a negative net margin of 2,520.57%. On average, analysts expect Prothena to post $1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Prothena Stock Down 3.8%

Shares of NASDAQ PRTA opened at $10.64 on Friday. The stock has a market capitalization of $572.75 million, a price-to-earnings ratio of -2.34, a PEG ratio of 0.37 and a beta of -0.23. The stock's fifty day simple moving average is $9.80 and its 200 day simple moving average is $9.79. Prothena has a 52-week low of $4.32 and a 52-week high of $11.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PRTA. Tower Research Capital LLC TRC grew its stake in Prothena by 571.0% in the second quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 10,815 shares in the last quarter. PDT Partners LLC purchased a new position in Prothena in the fourth quarter valued at about $108,000. Voleon Capital Management LP purchased a new position in Prothena in the second quarter valued at about $113,000. DRW Securities LLC purchased a new position in Prothena in the fourth quarter valued at about $114,000. Finally, Brooklyn Investment Group grew its stake in Prothena by 13.1% in the third quarter. Brooklyn Investment Group now owns 12,569 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 1,456 shares in the last quarter. Hedge funds and other institutional investors own 97.08% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PRTA shares. Stifel Nicolaus set a $19.00 target price on Prothena in a report on Friday, March 13th. Citigroup restated a "market outperform" rating on shares of Prothena in a report on Friday, March 13th. Royal Bank Of Canada lifted their target price on Prothena from $11.00 to $12.00 and gave the stock a "sector perform" rating in a report on Friday, February 20th. Finally, Weiss Ratings cut Prothena from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $21.67.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.